Supplementary Table 1. Survival according to the different PAH aetiologies

Survival (95% CI)	I/H/D-PAH	CTD-PAH	CHD-PAH
1 year	93 (90-95)	83 (77-87)	97 (93-99)
3 years	81 (76-84)	67 (60-73)	89 (83-93)
5 years	72 (67-76)	51 (43-57)	82 (75-88)
10 years	54 (49-59)	20 (14-27)	65 (55-72)

Legend: CHD, congenital heart disease; CI, confidence interval; CTD, connective tissue disease; I/H/D, idiopathic/heritable/drug-induced; PAH, pulmonary arterial hypertension

Supplementary Table 2. Multivariable Cox proportional hazards regression at baseline including BNP/NT-proBNP

	HR (95% CI)	p-value
Age, years	1.04 (1.02-1.05)	<0.001
Male gender	2.00 (1.42-2.81)	<0.001
CTD aetiology	1.66 (1.19-2.31)	0.003
6MWD, m	0.997 (0.995-0.998)	<0.001
BNP/NT-proBNP, vs <50/<300 ng/l		
- 50-200/300-650 ng/l	1.36 (0.84-2.21)	0.211
- 200-800/650-1100 ng/l	1.96 (1.19-3.21)	0.008
- >800/>1100 ng/l	2.29 (1.49-3.51)	<0.001

Legend: 6MWD, 6-minute walk distance; BNP, brain natriuretic peptide; CTD, connective tissue disease; NT-proBNP, N-terminal pro-hormone BNP

Supplementary Table 3. Correlation matrix of hemodynamic variables at 1st follow-up

Pearson Correlation	RAP	mPAP	sPAP	Ea	CE	RV power	RVSWI	RC product	CI	SVI	PVR	PAC	SvO2
RAP	1.000	0.338	0.333	0.317	-0.346	0.038	-0.105	0.089	-0.309	-0.279	0.312	-0.288	-0.413
mPAP	0.338	1.000	0.963	0.741	-0.723	0.601	0.580	0.410	-0.311	-0.362	0.812	-0.637	-0.211
sPAP	0.333	0.963	1.000	0.724	-0.726	0.593	0.585	0.260	-0.305	-0.337	0.770	-0.711	-0.234
Ea	0.317	0.741	0.724	1.000	-0.638	0.114	0.042	0.177	-0.509	-0.590	0.960	-0.583	-0.421
CE	-0.346	-0.723	-0.726	-0.638	1.000	-0.196	-0.142	-0.247	0.622	0.759	-0.663	0.878	0.441
RV power	0.038	0.601	0.593	0.114	-0.196	1.000	0.896	0.107	0.514	0.354	0.135	-0.180	0.373
RVSWI	-0.105	0.580	0.585	0.042	-0.142	0.896	1.000	0.287	0.393	0.447	0.136	-0.151	0.355
RC product	0.089	0.410	0.260	0.177	-0.247	0.107	0.287	1.000	-0.296	-0.102	0.369	0.054	-0.124
CI	-0.309	-0.311	-0.305	-0.509	0.622	0.514	0.393	-0.296	1.000	0.839	-0.562	0.547	0.680
SVI	-0.279	-0.362	-0.337	-0.590	0.759	0.354	0.447	-0.102	0.839	1.000	-0.570	0.636	0.606
PVR	0.312	0.812	0.770	0.960	-0.663	0.135	0.136	0.369	-0.562	-0.570	1.000	-0.589	-0.433
PAC	-0.288	-0.637	-0.711	-0.583	0.878	-0.180	-0.151	0.054	0.547	0.636	-0.589	1.000	0.420
SvO2	-0.413	-0.211	-0.234	-0.421	0.441	0.373	0.355	-0.124	0.680	0.606	-0.433	0.420	1.000

Legend: CE, cardiac efficiency; CI, cardiac index; Ea, pulmonary artery elastance; mPAP, mean pulmonary artery pressure; PAC, pulmonary arterial compliance; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RC, resistance-compliance; RV, right ventricle; RVSWI, RV stroke work index; sPAP, systolic pulmonary artery pressure; SVI, stroke volume index; SvO2, mixed venous oxygen saturation.

All correlations significant at the 0.02 level (2-tailed) but RC product*PAC, RV power*RAP, and Ea*RVSWI whose correlations were not statistically significant.

Supplementary Table 4. Comparison of multivariable cox regression models for hemodynamic variables at 1st follow-up excluding patients with uncorrected CHD and responder to CCBs treatment

	Baseline		1st F-UP Model 1		1st F-UP Model 2		1st F-UP Model 3	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age, y	1.03 (1.02-1.03)	<0.001	1.03 (1.02-1.04)	<0.001	1.03 (1.02-1.04)	<0.001	1.03 (1.02-1.04)	<0.001
Male gender	2.37 (1.83-3.07)	<0.001	2.07 (1.55-2.77)	<0.001	2.08 (1.55-2.79)	<0.001	1.84 (1.38-2.46)	<0.001
CTD aetiology	1.69 (1.31-2.19)	<0.001	1.90 (1.43-2.53)	<0.001	1.93 (1.44-2.57)	<0.001	1.87 (1.41-2.48)	<0.001
6MWD, 10 m	0.96 (0.95-0.97)	<0.001	0.9997 (0.9995-0.9999)*	0.002	0.9997 (0.9995-0.9999)*	0.001	0.9997 (0.9995-0.9999)*	0.003
WHO-FC			1.38 (1.08-1.77)	0.010	1.35 (1.05-1.73)	0.019	1.39 (1.09-1.78)	0.008
eGFR, ml/min	0.994 (0.988-0.9998)	0.043						
RAP, mmHg	1.04 (1.01-1.06)	0.003	1.07 (1.05-1.10)	<0.001	1.07 (1.04-1.10)	<0.001	1.07 (1.04-1.10)	<0.001
PAC, ml/mmHg			0.77 (0.64-0.92)	0.005				
Ea, mmHg/ml					1.34 (1.13-1.59)	0.001		
SvO_2, %							0.98 (0.96-0.99)	0.002
Log likelihood			-1373.09		-1373.47		-1374.00	
AIC			2760.18		2760.94		2762.00	
BIC			2789.69		2790.48		2791.54	
	1st F-UP Model 4		1st F-UP Model 5		1st F-UP Model 6		1st F-UP Model 7	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
Age, y	1.03 (1.02-1.04)	<0.001	1.03 (1.02-1.04)	<0.001	1.03 (1.02-1.04)	<0.001	1.03 (1.02-1.04)	<0.001
Male gender	2.06 (1.53-2.76)	<0.001	2.03 (1.52-2.72)	<0.001	1.84 (1.37-2.46)	<0.001	1.88 (1.40-2.51)	<0.001
CTD aetiology	1.96 (1.46-2.62)	<0.001	1.92 (1.44-2.56)	<0.001	1.87 (1.41-2.50)	<0.001	1.83 (1.38-2.43)	<0.001
6MWD, 10 m*	0.9997 (0.9996-0.9999)	0.001	0.9997 (0.9995-0.9999)	0.002	0.9997 (0.9995-0.9999)	0.001	0.9997 (0.9995-0.9999)	0.003
WHO-FC	1.36 (1.06-1.75)	0.015	1.38 (1.07-1.77)	0.012	1.44 (1.12-1.84)	0.001	1.42 (1.10-1.82)	0.006
RAP, mmHg	1.07 (1.04-1.10)	<0.001	1.07 (1.04-1.10)	<0.001	1.08 (1.05-1.11)	<0.001	1.08 (1.05-1.11)	<0.001
PVR, WU	1.04 (1.01-1.07)	0.002						
CE, ml/mmHg			0.76 (0.62-0.94) CE	0.010				
CI, l/min/m^2					0.84 (0.70-0.996)	0.045		
SVI, ml/m^2							0.99 (0.97-1.00)	0.063

Log likelihood	-1374.20	-1375.06	-1376.55	-1376.86
AIC	2762.41	2764.12	2767.09	2767.72
BIC	2791.95	2793.67	2796.64	2797.26

Legend: 6MWD, 6-minute walk distance; AIC, Akaike's information criterion; BIC, Bayesian information criterion; CE, cardiac efficiency; CI, cardiac index; CTD, connective tissue disease; Ea, pulmonary artery elastance; F-UP, follow-up; HR, hazard ratio; PAC, pulmonary arterial compliance; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SVI, stroke volume index; SvO2, mixed venous oxygen saturation; WHO-FC, world health organization functional class

*Time varying covariate

Supplementary Table 5. Bivariate analysis for all-cause mortality

Bivariate analysis	COMPERA 1.0		FPHR		Bologna simplified table		COMPERA 2.0	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
RAP								
<8 mmHg	ref		ref		ref		ref	
8-14 mmHg	1.26 (0.99-1.61)	0.060	1.06 (0.81-1.38)	0.674	1.32 (1.04-1.68)	0.020	1.50 (1.19-1.88)	<0.001
>14 mmHg	1.96 (1.17-3.27)	0.010	1.95 (1.25-3.06)	0.003	3.08 (1.61-5.90)	0.001	2.82 (1.89-4.21)	<0.001
Ea								
<1.1 mmHg/ml	ref		ref		ref		ref	
1.1-1.8 mmHg/ml	1.14 (0.87-1.48)	0.338	1.12 (0.86-1.46)	0.414	1.09 (0.84-1.43)	0.514	1.11 (0.85-1.44)	0.447
>1.8 mmHg/ml	0.98 (0.74-1.30)	0.878	0.99 (0.75-1.32)	0.972	1.05 (0.80-1.39)	0.730	1.25 (0.96-1.63)	0.096
PAC								
>1.5 ml/mmHg	ref		ref		ref		ref	
0.7-1.5 ml/mmHg	1.14 (0.89-1.46)	0.299	1.14 (0.89-1.47)	0.290	1.07 (0.84-1.38)	0.575	1.15 (0.90-1.46)	0.274
<0.7 ml/mmHg	1.05 (0.76-1.46)	0.760	1.07 (0.76-1.49)	0.709	1.14 (0.82-1.57)	0.444	1.38 (1.02-1.89)	0.040
CE								
>1.5 ml/mmHg	ref		ref		ref		ref	
0.8-1.5 ml/mmHg	1.15 (0.89-1.48)	0.284	1.07 (0.83-1.38)	0.615	1.09 (0.85-1.41)	0.505	1.10 (0.86-1.42)	0.442
<0.8 ml/mmHg	0.93 (0.69-1.26)	0.636	1.00 (0.74-1.35)	0.977	1.04 (0.78-1.40)	0.780	1.30 (0.98-1.72)	0.066
PVR								
<6 WU	ref		ref		ref		ref	
6-14 WU	1.13 (0.88-1.45)	0.342	1.08 (0.84-1.39)	0.559	1.04 (0.80-1.33)	0.789	1.18 (0.92-1.51)	0.185
>14 WU	0.82 (0.60-1.13)	0.226	0.81 (0.59-1.12)	0.200	0.87 (0.64-1.19)	0.397	1.12 (0.84-1.51)	0.437
SvO2								
>65 %	ref		ref		ref		ref	
60-65 %	0.92 (0.67-1.25)	0.592	1.29 (0.97-1.73)	0.079	1.07 (0.79-1.43)	0.675	1.30 (0.98-1.73)	0.074
<60 %	0.94 (0.69-1.27)	0.682	1.31 (0.98-1.76)	0.071	1.11 (0.83-1.50)	0.478	1.39 (1.06-1.81)	0.016
CI								
>2.5 l/min/m2	ref		ref		ref		ref	
2.0-2.5 l/min/m2	0.89 (0.67-1.19)	0.443	0.79 (0.58-1.07)	0.131	0.98 (0.74-1.30)	0.867	1.19 (0.90-1.56)	0.219
<2.0 l/min/m2	0.75 (0.54-1.04)	0.087	0.93 (0.67-1.29)	0.669	1.06 (0.79-1.43)	0.683	1.42 (1.07-1.88)	0.014
SVI								

>38 ml/m2	ref		ref		ref		ref	
31-38 ml/m2	1.00 (0.75-1.34)	0.999	1.00 (0.74-1.33)	0.980	0.94 (0.70-1.26)	0.671	0.92 (0.68-1.23)	0.557
<31 ml/m2	1.18 (0.89-1.56)	0.246	1.25 (0.94-1.66)	0.123	1.28 (0.97-1.68)	0.078	1.52 (0.18-1.96)	0.001

Legend: CE, cardiac efficiency; CI, cardiac index; COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; Ea, pulmonary artery elastance; FPHR, French pulmonary hypertension registry; PAC, pulmonary arterial compliance; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SVI, stroke volume index; SvO2, mixed venous oxygen saturation.

Supplementary Table 6. Bivariate analysis for all-cause mortality, all-cause non-elective hospitalization and need of treatment escalation.

Bivariate analysis	COMPERA 1.0		FPHR		Bologna simplified table		COMPERA 2.0	
	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value	HR (95% CI)	p-value
RAP								
<8 mmHg	ref		ref		ref		ref	
8-14 mmHg	1.27 (1.03-1.55)	0.023	1.11 (0.89-1.39)	0.335	1.30 (1.06-1.58)	0.011	1.48 (1.23-1.79)	<0.001
>14 mmHg	1.68 (1.04-2.72)	0.034	1.63 (1.09-2.45)	0.019	1.59 (0.94-2.69)	0.085	2.09 (1.44-3.04)	<0.001
Ea								
<1.1 mmHg/ml	ref		ref		ref		ref	
1.1-1.8 mmHg/ml	1.77 (1.44-2.19)	<0.001	1.74 (1.41-2.15)	<0.001	1.70 (1.38-2.11)	<0.001	1.69 (1.37-2.09)	<0.001
>1.8 mmHg/ml	1.84 (1.46-2.32)	<0.001	1.81 (1.43-2.28)	<0.001	1.89 (1.51-2.37)	<0.001	2.15 (1.73-2.66)	<0.001
PAC								
>1.5 ml/mmHg	ref		ref		ref		ref	
0.7-1.5 ml/mmHg	1.79 (1.47-2.17)	<0.001	1.77 (1.46-2.16)	<0.001	1.73 (1.42-2.10)	<0.001	1.78 (1.47-2.16)	<0.001
<0.7 ml/mmHg	1.81 (1.36-2.40)	<0.001	1.75 (1.31-2.33)	<0.001	1.89 (1.44-2.49)	<0.001	2.16 (1.66-2.79)	<0.001
CE								
>1.5 ml/mmHg	ref		ref		ref		ref	
0.8-1.5 ml/mmHg	2.03 (1.66-2.48)	<0.001	1.94 (1.58-2.37)	<0.001	1.95 (1.59-2.39)	<0.001	1.97 (1.61-2.41)	<0.001
<0.8 ml/mmHg	1.83 (1.42-2.34)	<0.001	1.88 (1.47-2.40)	<0.001	1.91 (1.50-2.44)	<0.001	2.23 (1.77-2.80)	<0.001
PVR								
<6 WU	ref		ref		ref		ref	
6-14 WU	2.02 (1.65-2.47)	<0.001	1.99 (1.63-2.43)	<0.001	1.96 (1.60-2.40)	<0.001	2.06 (1.69-2.51)	<0.001
>14 WU	1.93 (1.50-2.49)	<0.001	1.88 (1.45-2.43)	<0.001	1.94 (1.50-2.50)	<0.001	2.30 (1.81-2.93)	<0.001
SvO2								
>65 %	ref		ref		ref		ref	
60-65 %	1.31 (1.02-1.69)	0.038	1.56 (1.23-1.97)	<0.001	1.32 (1.03-1.69)	0.031	1.59 (1.25-2.02)	<0.001
<60 %	1.47 (1.13-1.92)	0.004	1.61 (1.25-2.07)	<0.001	1.48 (1.14-1.91)	0.003	1.75 (1.39-2.20)	<0.001
CI								
>2.5 l/min/m2	ref		ref		ref		ref	
2.0-2.5 l/min/m2	1.60 (1.26-2.03)	<0.001	1.45 (1.14-1.86)	0.003	1.58 (1.25-2.00)	<0.001	1.81 (1.45-2.26)	0.003
<2.0 l/min/m2	1.41 (1.06-1.89)	0.019	1.56 (1.19-2.06)	0.002	1.61 (1.24-2.09)	<0.001	1.96 (1.54-2.50)	0.002
SVI								

>38 ml/m2	ref		ref		ref		ref	
31-38 ml/m2	1.53 (1.22-1.91)	<0.001	1.48 (1.18-1.85)	0.001	1.42 (1.13-1.78)	0.002	1.44 (1.15-1.80)	0.002
<31 ml/m2	2.01 (1.60-2.53)	<0.001	2.01 (1.60-2.53)	<0.001	2.03 (1.62-2.55)	<0.001	2.31 (1.87-2.85)	<0.001

Legend: CE, cardiac efficiency; CI, cardiac index; COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; Ea, pulmonary artery elastance; FPHR, French pulmonary hypertension registry; PAC, pulmonary arterial compliance; PVR, pulmonary vascular resistance; RAP, right atrial pressure; SVI, stroke volume index; SvO2, mixed venous oxygen saturation.

Supplementary Table 7. Risk discrimination characteristics of the proposed RHC risk tool 3-strata vs COMPERA 1.0, FPHR and Bologna simplified risk table strategies and of the proposed RHC risk tool 4-strata vs COMPERA 2.0 risk tool for the combined endpoint (all cause death + all-cause non-elective hospitalization + need of treatment escalation) in patients with available BNP/NT-proBNP at 1st follow-up (n= 151)

	All cause death + PAH-related non-elective hospitalization + need of treatment escalation			
	RHC risk tool 3-strata	**COMPERA 1.0**	**FPHR**	**Bologna**
C-statistic (95% CI)	0.636 (0.582-0.689)	0.600 (0.542-0.657)	0.594 (0.534-0.653)	0.574 (0.524-0.624)
AIC	791.01	787.87	787.46	794.37
BIC	794.06	790.92	790.51	797.42
1-y event-free survival (%) - Low - Intermediate - High	 89.6 (79.4-94.9) 57.2 (44.7-67.9) 37.5 (8.7-67.4)	 84.6 (73.3-91.5) 61.8 (50.1-71.6) NA	 82.9 (70.5-90.4) 69.5 (57.7-78.6) 23.1 (4.3-50.5)	 89.5 (74.3-95.9) 65.2 (55.2-73.6) 66.7 (19.5-90.4)
p-value	p >0.05 for all pairwise comparisons.			
	RHC risk tool 4-strata		**COMPERA 2.0**	
C-statistic (95% CI)	0.684 (0.626-0.741)		0.609 (0.544-0.673)	
AIC	778.52		786.47	
BIC	781.57		789.52	
1-y event-free survival (%) - Low - Intermediate-low - Intermediate-high - High	 92.8 (82.0-97.2) 72.1 (58.1-82.2) 37.8 (21.2-54.3) 25.0 (0.9-66.5)		 84.1 (70.6-91.7) 77.8 (64.2-86.7) 54.3 (37.0-68.7) 28.6 (0.4-61.1)	
p-value	0.060			

Legend: AIC, Akaike's information criterion; BIC, Bayesian information criterion; COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; FPHR, French Pulmonary Hypertension Registry; RHC, right heart catheterization.

Supplementary Table 8. Risk discrimination characteristics of the proposed RHC risk tool 3-strata vs COMPERA 1.0, FPHR and Bologna simplified risk table strategies and of the proposed RHC risk tool 4-strata vs COMPERA 2.0 risk tool for the combined endpoint (all cause death + PAH-related non-elective hospitalization + need of treatment escalation)

	All cause death + PAH-related non-elective hospitalization + need of treatment escalation			
	RHC risk tool 3-strata	**COMPERA 1.0**	**FPHR**	**Bologna**
C-statistic (95% CI)	0.666* (0.644-0.689)	0.647 (0.625-0.668)	0.646 (0.623-0.669)	0.640* (0.618-0.663)
AIC	5906.79	5920.80	5927.45	5933.45
BIC	5911.35	5925.36	5932.01	5938.01
1-y event-free survival (%) - Low - Intermediate - High	 91.6 (87.4-94.4) 69.4 (64.0-74.2) 46.1 (36.8-54.9)	 86.7 (83.0-89.7) 59.4 (53.2-64.9) 28.0 (12.4-46.0)	 86.6 (82.6-89.7) 68.2 (62.1-73.5) 33.3 (22.9-44.0)	 87.8 (83.6-91.0) 66.2 (61.0-70.9) 37.1 (22.7-51.6)
	RHC risk tool 4-strata		**COMPERA 2.0**	
C-statistic (95% CI)	0.682 (0.658-0.705)		0.659 (0.636-0.682)	
AIC	5884.35		5894.95	
BIC	5888.91		5899.50	
1-y event-free survival (%) - Low - Intermediate-low - Intermediate-high - High	 92.4 (88.0-95.2) 81.4 (75.2-86.2) 59.8 (52.6-66.2) 37.3 (26.5-48.1)		 88.7 (84.7-91.7) 76.3 (68.9-82.2) 52.9 (45.6-59.6) 31.8 (14.2-51.1)	

Legend: AIC, Akaike's information criterion; BIC, Bayesian information criterion; COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; FPHR, French Pulmonary Hypertension Registry; RHC, right heart catheterization. *= $p<0.05$ for the comparison

Supplementary Table 9. Risk discrimination characteristics of the COMPERA-RHC 4-strata risk tool vs COMPERA 2.0 risk tool for the combined endpoint (all cause death + all cause non-elective hospitalization + need of treatment escalation)

All patients (n= 706)	**All cause death + all cause non-elective hospitalization + need of treatment escalation**	
	COMPERA 2.0	**COMPERA-RHC 4-strata**
C-statistic (95% CI)	0.655 (0.632-0.678)	0.683 (0.661-0.705)
AIC	6075.77	6038.37
BIC	6080.33	6042.93
1-y event-free survival (%) - Low - Intermediate-low - Intermediate-high - High	 86.5 (82.2-89.8) 73.2 (65.6-79.3) 48.7 (41.5-55.5) 31.8 (14.2-51.1)	 91.1 (86.3-94.2) 77.5 (72.1-82.0) 42.9 (35.7-50.0) 30.4 (13.5-49.3)
	p-value= 0.005	
Only patients with BNP (n= 151)	**All cause death + all cause non-elective hospitalization + need of treatment escalation**	
	COMPERA 2.0	**COMPERA-RHC 4-strata**
C-statistic (95% CI)	0.609 (0.544-0.673)	0.670 (0.618-0.721)
AIC	786.47	776.56
BIC	789.52	779.61
1-y event-free survival (%) - Low - Intermediate-low - Intermediate-high - High	 84.1 (70.6-91.7) 77.8 (64.2-86.7) 54.3 (37.0-68.7) 28.6 (0.4-61.1)	 100 (NA) 76.9 (65.8-84.8) 37.1 (22.0-52.1) NA
	p-value= 0.023	

Legend: AIC, Akaike's information criterion; BIC, Bayesian information criterion; COMPERA, Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; RHC, right heart catheterization.

Supplementary Figure 1. Survival according to the different PAH aetiologies from baseline evaluation.



Legend: CHD, congenital heart disease; CTD, connective tissue disease; I/H/D, idiopathic/heritable/drug induced; PAH, pulmonary arterial hypertension. Log-rank test p-value I/H/D vs CHD= 0.095; I/H/D vs CTD <0.001; CHD vs CTD <0.001

Supplementary Figure 2. Line graph of different cut-off values and the corresponding chi2 of the long-rank test for the relative hemodynamic variables at 1st follow-up. Arrows indicate the cut-offs with the highest chi2 and the corresponding 1-y mortality.









Legend: CE, cardiac efficiency; Ea, pulmonary artery elastance; PAC, pulmonary arterial compliance; PVR, pulmonary vascular resistance.